Clinical efficacy and safety of zoledronic acid in prostate and breast cancer

Doggrell, Sheila (2009) Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Review of Anticancer Therapy, 9(9), pp. 1211-1218.

View at publisher


The anti-estrogen treatment for hormone-sensitive breast cancer and the androgen deprivation therapy for prostate cancer can lead to the development of osteoporosis and bone fractures. Metastases associated with prostate and breast cancer can also occur in bone. Bisphosphonates are used in these types of bone dysfunction. Zoledronic acid is the most potent bisphosphonate. In osteoporosis, zoledronic acid inhibits bone reabsorption and increases bone mineral density for at least a year after intravenous administration. The efficacy and safety of zoledronic acid in osteoporosis secondary to hormone-sensitive cancers (prostate and breast), and in the bone metastases associated with these cancers are reviewed.

Impact and interest:

17 citations in Scopus
13 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

367 since deposited on 13 Jan 2010
38 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 29671
Item Type: Journal Article
Refereed: Yes
Additional URLs:
Keywords: zoledronic acid, bone metastases, breast cancer, osteoporosis, prostate cancer
DOI: 10.1586/era.09.95
ISSN: 1473-7140
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Clinical Pharmacology and Therapeutics (111502)
Divisions: Past > QUT Faculties & Divisions > Faculty of Science and Technology
Copyright Owner: Copyright 2009 Expert Reviews Ltd.
Deposited On: 13 Jan 2010 22:10
Last Modified: 19 Jan 2012 05:38

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page